AMSBIO and Genea Biocells partner for distribution of skeletal muscle differentiation kit

AMSBIO has signed an agreement with Genea Biocells (San Diego, USA) to become global distribution partner to the academic community for its groundbreaking skeletal muscle differentiation product range.

Genea Biocells developed the world’s first protocol to robustly differentiate human pluripotent stem cells to skeletal muscle cells with high yields and without cell sorting or genetic manipulation (Caron et al. 2016). Leveraging AMSBIO’s international marketing reach and technical support team this exciting technology has already gained significant uptake in labs.

Phillip Pridham-Field, Stem Cell Products Business Unit Manager at AMSBIO commented:

Genea Biocells skeletal muscle differentiation kit provides researchers with a unique tool to rapidly differentiate stem cells into functional myotubes in a reproducible fashion. Tested on a wide range of human embryonic and induced pluripotent stem cell lines the kit follows a simple 3-step process of media changes and cell passaging. Eliminating the need for cell sorting or transfection of myogenic transcription factors, the three-step protocol used generates a highly pure population of approximately 70 per cent skeletal muscle myotubes in just a few weeks”. He added “Our life science customers are using the kit to provide new methods of studying developmental biology, novel approaches to producing accurate disease models, new techniques to help drug discovery and also in toxicity testing.

Uli Schmidt, President at Genea Biocells said:

We are delighted to have partnered with AMSBIO for the distribution of our skeletal muscle differentiation kit.  Having such a reputable company with global reach to market our products allows our scientists, as well as the academic community, to focus on research towards a better understanding of neuromuscular diseases and hopefully accelerate therapeutic research to treat these devastating indications.

AMSBIO are an international leader in innovative products for stem cell research. The recent launch of StemFit - a xeno-free, defined medium proven to effectively maintain iPS and ES cells under feeder-free conditions during stem cell culture has been enthusiastically received by the research community.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    AMS Biotechnology. (2018, March 23). AMSBIO and Genea Biocells partner for distribution of skeletal muscle differentiation kit. News-Medical. Retrieved on May 21, 2019 from https://www.news-medical.net/news/20180323/AMSBIO-and-Genea-Biocells-partner-for-distribution-of-skeletal-muscle-differentiation-kit.aspx.

  • MLA

    AMS Biotechnology. "AMSBIO and Genea Biocells partner for distribution of skeletal muscle differentiation kit". News-Medical. 21 May 2019. <https://www.news-medical.net/news/20180323/AMSBIO-and-Genea-Biocells-partner-for-distribution-of-skeletal-muscle-differentiation-kit.aspx>.

  • Chicago

    AMS Biotechnology. "AMSBIO and Genea Biocells partner for distribution of skeletal muscle differentiation kit". News-Medical. https://www.news-medical.net/news/20180323/AMSBIO-and-Genea-Biocells-partner-for-distribution-of-skeletal-muscle-differentiation-kit.aspx. (accessed May 21, 2019).

  • Harvard

    AMS Biotechnology. 2018. AMSBIO and Genea Biocells partner for distribution of skeletal muscle differentiation kit. News-Medical, viewed 21 May 2019, https://www.news-medical.net/news/20180323/AMSBIO-and-Genea-Biocells-partner-for-distribution-of-skeletal-muscle-differentiation-kit.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
AMSBIO's Detachin provides rapid and efficient cell detachment